Mod­er­na's new Covid-19 vac­cine analy­sis 'giv­ing weight' to an­nu­al boost­ing in­ter­val, com­pa­ny says

Mod­er­na’s Covid-19 vac­cine study sug­gests a longer in­ter­val be­tween boost­ers is more ben­e­fi­cial in the gen­er­al adult pop­u­la­tion, sup­port­ing the FDA’s pre­vi­ous pro­pos­al for an an­nu­al boost­ing strat­e­gy.

Mod­er­na an­a­lyzed the ef­fi­ca­cy of a sin­gle boost­er of its orig­i­nal vac­cine in around 17,000 par­tic­i­pants en­rolled in its Phase III COVE study from Sept. 2021 to May 2022, the com­pa­ny an­nounced Wednes­day at the ID­Week con­fer­ence in Boston. The tri­al in­clud­ed par­tic­i­pants who re­ceived a boost­er shot rough­ly 12 to 13 months af­ter their pri­ma­ry se­ries, as well as those who ini­tial­ly re­ceived a place­bo be­fore mov­ing to the open-la­bel phase and were boost­ed af­ter rough­ly eight months, ac­cord­ing to Fran Prid­dy, ex­ec­u­tive di­rec­tor of clin­i­cal de­vel­op­ment in Mod­er­na’s Covid vac­cines unit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER